Corcept Therapeutics Signals Big Growth After Key Wins

Corcept Therapeutics ((CORT)) has held its Q1 earnings call. Read on for the main highlights of the call.

Corcept Therapeutics’ latest earnings call mixed strong scientific wins with temporary financial growing pains. Executives struck a confident tone as they highlighted landmark data, a major new oncology approval and accelerating prescription trends, even while acknowledging a swing to quarterly loss, near‑term revenue friction and operational bottlenecks that they insist are manageable.

Quarterly Revenue Growth and Raised 2026 Outlook

Corcept reported Q1 2026 revenue of $164.9 million, up about 4.9% from $157.2 million a year earlier, reflecting modest top‑line growth despite several headwinds. On the back of this performance and a strengthening demand backdrop, management lifted full‑year 2026 revenue guidance to a range of $950 million to $1.05 billion, signaling confidence in the underlying trajectory.

Robust Cash Reserves Support Investment Plans

The company closed the quarter with $515 million in cash and investments as of March 31, 2026, giving it substantial flexibility to fund commercialization and late‑stage trials. Management framed this balance sheet strength as a key asset that allows Corcept to absorb short‑term earnings volatility while pursuing multiple high‑impact programs in parallel.

Endocrinology Franchise Demand Hits Record Levels

Corcept’s endocrinology franchise delivered record new prescriptions, record numbers of prescribers and record total patients on therapy, underscoring durable demand. New patient starts hit all‑time highs in March and then again in April, suggesting that underlying volume growth is accelerating even though some of that strength is not yet fully visible in reported revenue.

CATALYST and MOMENTUM Poised to Expand Cushing’s Market

Landmark CATALYST data showed that 24% of patients with resistant diabetes have hypercortisolism and that treatment with Korlym cut HbA1c, weight and waist circumference, findings now published in Diabetes Care and cited in AACE guidance. MOMENTUM showed 27% of resistant hypertension patients have hypercortisolism, and management believes these results will drive broader screening and treatment, supporting a Cushing’s business they see reaching at least $2 billion annually by decade‑end.

Early Lifyorli Approval and Strong ROSELLA Survival Benefit

Lifyorli secured FDA approval for platinum‑resistant ovarian cancer 3.5 months ahead of its decision date, a notable regulatory win in a hard‑to‑treat setting. The pivotal ROSELLA trial, now published in The Lancet, showed Lifyorli plus nab‑paclitaxel cut the risk of death by 35% with a hazard ratio of 0.65 and no biomarker restriction, opening the door to broad clinical use.

Lifyorli Launch Gains Quick Commercial Momentum

The company moved from approval to product availability in just five days, and within roughly 36 days more than 200 physicians across community oncology, gynecology and academic centers had written prescriptions. Lifyorli was added as a preferred regimen in NCCN guidelines just 15 days post‑approval, and management projects the drug could generate over $1 billion in annual U.S. revenue by the end of the decade.

ALS and MASH Pipeline Assets Show High‑Impact Potential

In ALS, the DAZALS study of dazucorilant 300 mg reported an 84% reduction in risk of death at one year and 87% at two years, with a pivotal Phase III planned later this year using survival as the primary endpoint. In liver disease, the miricorilant MONARCH Phase IIb trial in MASH is fully enrolled with 175 patients and data expected by year‑end, building on earlier Phase Ib results that showed rapid liver fat loss and improved fibrosis markers.

Broader Oncology Pipeline Advances Beyond Lifyorli

Outside Lifyorli, Corcept is in discussions with the FDA on a relacorilant NDA in Cushing’s syndrome, aiming to deepen its endocrine leadership. In oncology, the BELLA trial testing relacorilant with nab‑paclitaxel and bevacizumab has first‑arm data due by year‑end, while additional relacorilant and nenocorilant studies, including a Phase Ib with nivolumab, should deliver a steady flow of readouts through next year.

Shift to Net Loss Reflects Investment and Launch Costs

Despite rising revenue, Corcept posted a Q1 2026 net loss of $31.8 million versus net income of $20.5 million in the prior‑year quarter, a negative swing of $52.3 million. Management implicitly linked this reversal to launch expenses, R&D investment and temporary revenue timing issues, presenting the loss as a strategic trade‑off to build larger future revenue streams.

Insurance Reauthorizations Weigh on First‑Quarter Revenue

Executives emphasized that first‑quarter revenue for rare‑disease therapies is routinely pressured by insurance reauthorization cycles, which can disrupt coverage for one to two months. Corcept bridges these gaps with free drug programs, protecting patients but depressing near‑term recognized revenue, a dynamic they characterize as seasonal rather than structural.

Specialty Pharmacy Switch Creates Temporary Authorization Backlog

The company’s transition of thousands of patients to a new specialty pharmacy created a backlog of prior authorizations that has delayed some revenue recognition. Corcept is working through the paperwork and expects this drag to unwind over the coming months, turning what is now a headwind into a tailwind as the backlog clears.

Oncology Still a Small Contributor to Near‑Term Guidance

While Lifyorli’s debut has been encouraging, management cautioned that oncology remains an early‑stage revenue stream and is not yet a major contributor to 2026 guidance. The updated outlook is still anchored mainly by the established endocrine business, suggesting meaningful upside if oncology ramps faster than currently embedded in forecasts.

Managing DAZALS Tolerability to Protect ALS Opportunity

In DAZALS, most discontinuations were due to nonserious gastrointestinal distress, a safety profile the company believes can be managed but which still poses a risk to long‑term adherence and trial enrollment. Corcept has launched a dose‑titration study aimed at improving GI tolerability before Phase III, an effort seen as critical to securing regulatory support in ALS.

Scaling Specialty Pharmacy Capacity to Match Demand

Management acknowledged that current and projected prescription volumes will outgrow the capacity of a single specialty pharmacy, creating an operational bottleneck if unaddressed. Plans are underway to expand the pharmacy network with additional support targeted by the fourth quarter, a step they view as necessary to sustain growth and improve patient onboarding times.

New Patient Dynamics Create Revenue Recognition Lag

The surge in new patient starts, while strategically attractive, generates lower initial revenue because coverage approvals and dose titration must be completed before full billing. This lag effect means today’s volume growth will translate into more pronounced revenue gains over subsequent quarters, adding an element of timing complexity for investors tracking quarterly trends.

Guidance and Long‑Term Growth Vision

Corcept’s raised 2026 revenue guidance to $950 million–$1.05 billion leans heavily on its endocrine franchise, with management explicitly targeting at least $2 billion in annual Cushing’s revenues and over $1 billion in U.S. Lifyorli sales by decade‑end. Backed by $515 million in cash, pivotal trials in ALS and MASH and ongoing oncology readouts, the company plans to expand its specialty pharmacy network by Q4 to support the higher volumes implied by this ambitious roadmap.

Corcept’s earnings call painted a picture of a company trading short‑term noise for long‑term scale, with modest current revenue growth and a temporary loss contrasted against breakthrough clinical data and expanding commercial reach. For investors, the story now hinges on execution: clearing operational bottlenecks, confirming pivotal trial results and converting robust prescription momentum into the billion‑dollar franchises management envisions.